April 27 (Reuters) - U.S. stocks edged lower in Monday
afternoon trading, led by losses in the Nasdaq and biotech
shares including Amgen.

The Nasdaq Biotech Index was down 3.7 percent, on
track for its biggest daily percentage loss in about a month,
while the S&P Healthcare index, down 1.3 percent, was
the biggest drag on the benchmark S&P 500 index.

Amgen shares dropped 3.2 percent to $162.53 after
U.S. Food and Drug Administration staff reviewers said Amgen's
skin cancer immunotherapy cannot be considered for an
accelerated review at this time, citing concerns over the design
and results of a key study.

Drug developer Celladon Corp shares fell 80 percent
to $2.68 and hit a record low. It said it expected to announce
layoffs and cost cuts after the company's lead experimental gene
therapy to treat heart failure failed a key trial.
Continuación...